2 FTSE 100 stocks I’d buy today and hold forever in a Stocks and Shares ISA

These two FTSE 100 (INDEXFTSE:UKX) shares could offer high long-term returns, in my opinion.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

The FTSE 100 may be facing a period of uncertainty, due to risks such as coronavirus and geopolitical uncertainty in the US and Europe. However, there are a number of large-cap shares which appear to offer good value for money at present, due to their long-term growth potential.

With that in mind, here are two stocks that could be worth buying today through a tax-efficient account such as a Stocks and Shares ISA. They appear to have favourable long-term operating environments which may catalyse their financial performances in the coming years.

GSK

The next couple of years will be a period of significant change for GSK (LSE: GSK). Its separation into two companies could create a degree of uncertainty, which may cause investor sentiment to weaken. However, the end result is set to be a more focused biopharma company, as well as a leader in consumer healthcare.

The long-term growth potential for both businesses appears to be high. A growing, ageing world population could provide rising demand for a wide range of healthcare products. This could help to stimulate the company’s bottom line following its relatively lacklustre 1% rise in earnings in the 2020 financial year.

The stock’s price-to-earnings (P/E) ratio of 14.6 suggests it currently offers a wide margin of safety. Alongside its dividend yield of 4.6%, the company could offer the chance for investors to generate improving total returns – especially as it has the potential to become leaner and more focused as two companies. As such, now could be the right time to buy a slice of the business while it appears to offer good value for money.

Segro

Another FTSE 100 company which could have a bright long-term future is real estate investment trust (REIT) Segro (LSE: SGRO). It owns a range of warehouses across the UK and Europe which have experienced high demand from online retailers in recent years.

That trend looks set to continue, with suitable large warehouses seemingly in short supply. Segro reported in its recent quarterly update that demand for its properties has been high, and that rental growth has been buoyant. This could contribute to rising profitability over the long run, while over the next two years it’s expected to post an increase in its net profit of 8% per annum.

Segro’s price-to-book (P/B) ratio of 1.5 may be substantially higher than many of its REIT sector peers. However, its stronger financial prospects and the high demand for its properties means is could be worthy of a premium valuation. The long-term growth potential of online retailing suggests further share price growth could be ahead for the company following its 40% rise over the past year.

As such, buying it today, and holding it for the long run, could be a shrewd move.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »